Skip to main content
Back
Watch Compare

Liminatus Pharma, Inc.

Data quality: 83%
Also listed as LIMNW NASDAQ
LIMN
NASDAQ Manufacturing Chemicals
$0.19
▲ $0.01 (3.23%)
6 months return
—
Momentum
Neutral
Free cash flow
-9.98 M

Growth

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Quality

Return on Equity
N/A
ROICN/A
Net MarginN/A
Op. MarginN/A

Safety

Debt / Equity
N/A
Current Ratio0.42
Interest Coverage-13.75

Valuation

PE (TTM)
-0.91
Above sector avg (-1.49)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A

Quick Summary

Key Takeaways

Short bullets derived from reported financials—not the AI summary above.

Negative free cash flow of -9.98 M

Price History

Financial Trends

Analyst Price Target

No analyst coverage available

Growth

Rev 5Y: N/A · Earnings 1Y: N/A
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A

Profitability

ROE: N/A · Net Margin: N/A
Revenue (TTM) N/A Net Income (TTM) -10.21 M
ROE N/A ROA -627.86%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -9.98 M
ROIC N/A FCF Growth (3Y) N/A

Safety

D/E: N/A · Current: 0.42
Debt / Equity N/A Current Ratio 0.42
Interest Coverage -13.75 Asset Turnover N/A
Working Capital -1.66 M Tangible Book Value -1.65 M

Dividends

Yield: N/A · Payout: N/A
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A

Valuation

P/E: -0.91 · EV/EBITDA: N/A
P/E Ratio -0.91 Forward P/E N/A
P/B Ratio N/A P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -107.91%
Market Cap 9.24 M Enterprise Value 10.69 M

Per Share

EPS: -0.43 · FCF/Share: -0.22
EPS (Diluted TTM) -0.43 Revenue / Share N/A
FCF / Share -0.22 OCF / Share -0.22
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A

Efficiency

FCF Conv: 97.75% · CapEx/Rev: N/A
CapEx / Revenue N/A FCF Conversion 97.75%
SBC-Adj. FCF N/A Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025
Revenue —
Net Income -10.21 M
EPS (Diluted) -0.43
Gross Profit —
Operating Income -2.97 M
EBITDA —
R&D Expenses 2.69 M
SG&A Expenses —
D&A —
Interest Expense 215,903.0
Income Tax —

Balance Sheet

Annual, most recent first
Metric FY2025
Total Assets 512,795.0
Total Liabilities 10.33 M
Shareholders' Equity -9.81 M
Total Debt 1.44 M
Cash & Equivalents —
Current Assets 500,574.0
Current Liabilities 10.30 M

Peer Comparison

vs Manufacturing sector median (1605 peers)
Metric Stock Sector Median
P/E -0.9 -1.5
P/B — 1.6
ROE % — -54.5
Net Margin % — -41.5
Rev Growth 5Y % — 1.8
D/E — 0.3